Shots: Post EMA’s ODD, A4250 has received FDA’s ODD following its P-III study assessing A4250 in patients with Alagille syndrome, biliary atresia and primary biliary cholangitis (PBC) FDA has granted ODD to A4250 for the treatment of Alagille syndrome and primary biliary cholangitis and has also received EMA’s ODD on 18 Dec, 2018 with PRIority […]Read More
